These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12108530)

  • 1. Using an explicit guideline-based criterion and implicit review to assess antipsychotic dosing performance for schizophrenia.
    Owen RR; Thrush CR; Hudson TJ; Mallory SR; Fischer EP; Clardy JA; Williams DK
    Int J Qual Health Care; 2002 Jun; 14(3):199-206. PubMed ID: 12108530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Explicit versus implicit review to explore combination antipsychotic prescribing.
    Wheeler A
    J Eval Clin Pract; 2009 Aug; 15(4):685-91. PubMed ID: 19674220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical practice variations in prescribing antipsychotics for patients with schizophrenia.
    Owen RR; Fischer EP; Kirchner JE; Thrush CR; Williams DK; Cuffel BJ; Elliott CE; Booth BM
    Am J Med Qual; 2003; 18(4):140-6. PubMed ID: 12934949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic dosage at hospital discharge and outcomes among persons with schizophrenia.
    Sohler NL; Walkup J; McAlpine D; Boyer C; Olfson M
    Psychiatr Serv; 2003 Sep; 54(9):1258-63. PubMed ID: 12954943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delays in adopting evidence-based dosages of conventional antipsychotics.
    Valenstein M; Copeland L; Owen R; Blow F; Visnic S
    Psychiatr Serv; 2001 Sep; 52(9):1242-4. PubMed ID: 11533400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with schizophrenia at risk for excessive antipsychotic dosing.
    Walkup JT; McAlpine DD; Olfson M; Labay LE; Boyer C; Hansell S
    J Clin Psychiatry; 2000 May; 61(5):344-8. PubMed ID: 10847308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance measurement for schizophrenia: adherence to guidelines for antipsychotic dose.
    Owen RR; Thrush CR; Kirchner JE; Fischer EP; Booth BM
    Int J Qual Health Care; 2000 Dec; 12(6):475-82. PubMed ID: 11202601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic dosing patterns for schizophrenia in three treatment settings.
    Remington G; Shammi CM; Sethna R; Lawrence R
    Psychiatr Serv; 2001 Jan; 52(1):96-8. PubMed ID: 11141536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effectiveness of guideline implementation strategies on improving antipsychotic medication management for schizophrenia.
    Owen RR; Hudson T; Thrush C; Thapa P; Armitage T; Landes RD
    Med Care; 2008 Jul; 46(7):686-91. PubMed ID: 18580387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mental Health QUERI Initiative: expert ratings of criteria to assess performance for major depressive disorder and schizophrenia.
    Owen RR; Cannon D; Thrush CR;
    Am J Med Qual; 2003; 18(1):15-20. PubMed ID: 12583641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candidate gene analysis of pharmacodynamic targets for antipsychotic dosage.
    Hettige NC; de Moraes GH; Kennedy JL; De Luca V
    Pharmacogenomics; 2016 Feb; 17(3):199-208. PubMed ID: 26780210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors.
    Leslie DL; Rosenheck RA
    Med Care; 2001 Sep; 39(9):923-33. PubMed ID: 11502950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between adherence to guidelines for antipsychotic dose and health status, side effects, and patient care experiences.
    Dickey B; Normand SL; Eisen S; Hermann R; Cleary P; Cortés D; Ware N
    Med Care; 2006 Sep; 44(9):827-34. PubMed ID: 16932134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of public sector care for schizophrenia in Arkansas.
    Fischer EP; Owen RR
    Ment Health Serv Res; 1999 Dec; 1(4):213-21. PubMed ID: 11256727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Study of the Impact of Cannabis on Doses of Discharge Antipsychotic Medication in Individuals with Schizophrenia or Schizoaffective Disorder.
    Babatope T; Chotalia J; Elkhatib R; Mohite S; Shah J; Goddu S; Patel RA; Aimienwanu OR; Patel D; Makanjuola T; Okusaga OO
    Psychiatr Q; 2016 Dec; 87(4):729-737. PubMed ID: 26875104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using a computer database to monitor compliance with pharmacotherapeutic guidelines for schizophrenia.
    Chen RS; Nadkarni PM; Levin FL; Miller PL; Erdos J; Rosenheck RA
    Psychiatr Serv; 2000 Jun; 51(6):791-4. PubMed ID: 10828112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benchmarking the quality of schizophrenia pharmacotherapy: a comparison of the Department of Veterans Affairs and the private sector.
    Leslie DL; Rosenheck RA
    J Ment Health Policy Econ; 2003 Sep; 6(3):113-21. PubMed ID: 14646004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicians' reasons for deviations from recommended dosing practices for antipsychotic medications.
    Sernyak MJ; Rosenheck R
    Adm Policy Ment Health; 2007 Nov; 34(6):540-7. PubMed ID: 17957463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chlorpromazine dose for people with schizophrenia.
    Liu X; De Haan S
    Cochrane Database Syst Rev; 2009 Apr; (2):CD007778. PubMed ID: 19370692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroleptic dose: a statistical model for analyzing historical trends.
    Hargreaves WA; Zachary R; LeGoullon M; Binder R; Reus V
    J Psychiatr Res; 1987; 21(3):199-214. PubMed ID: 2890763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.